Older, Less Affluent Adults More Often Receiving an Opioid Prescription for Pain
Data for this study were sourced from the National Health Interview Survey (NHIS) which was conducted in 2019.
Opioids
Nalmefene HCl Injection Now Available for Opioid Overdose Treatment
Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.
Polysubstance Use Common in Adults Seeking Substance Use Treatment
Past 30-day polysubstance use is reported by 32.6% of adults who seek substance use treatment in the United States.
IV Acetaminophen Decreased Perioperative Opioid Use in Older Adults With Polytrauma
The use of intravenous acetaminophen as first-line therapy for older adults with polytrauma reduced perioperative opioid use.
Drop in Patients Receiving Opioids Noted From 2016 to 2019
From 2016 to 2019, there was a decline in the percentage of patients receiving concurrent opioid and benzodiazepine prescriptions.
Effects of Social Vulnerability on Geographic Access to Opioid Use Disorder Medications
This cross-sectional geospatial analysis was conducted by investigators at the University of Chicago using the social vulnerability index data from the CDC and data from SAMHSA.
Persistent Opioid Use After Sarcoma Treatment Explored Among Youth
Twenty-three percent of AYAs with sarcoma who were previously opioid-naive and use opioids during treatment have new persistent opioid use after treatment.
Rapid Opioid Dose Reduction Increases Overdose Risk in Long-Term, High-Dose Users
Rapid opioid dose reduction or discontinuation exceeding existing pain management guidelines was linked to increased opioid-related harm risk.
High-Dose Gabapentin Linked to Delayed Time to First Opioid Use in Oral Mucositis
For patients receiving concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck, higher doses of gabapentin are well tolerated and associated with delayed time to first opioid use for additional pain control during radiotherapy.
FDA Modifies REMS Requirements for Sublingual Sufentanil
Dsuvia, an opioid agonist, is a Schedule II controlled substance and is indicated for use in adults in a certified medically supervised healthcare setting.
- Loading...
Loading...
Next post in Opioid Addiction
Loading... 
Loading...